Stock MESO MESOBLAST LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Mesoblast Limited Nasdaq

Equities

MESO

US5907174016

Market Closed - Nasdaq
Other stock markets
 01:30:00 03/07/2024 am IST 		5-day change 1st Jan Change
6.45 USD -4.87% Intraday chart for Mesoblast Limited -4.30% +193.18%
02/07 Mesoblast to File Biological License Application with US FDA for Cellular Therapy MT
01/07 Mesoblast to File Biologics License Application for Ryoncil MT

Analyst Reco.

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Cantor Fitzgerald Adjusts Price Target on Mesoblast to $17 From $23, Maintains Overweight Rating
MT
Maxim Downgrades Mesoblast to Hold From Buy
MT
Piper Sandler Downgrades Mesoblast to Neutral From Overweight, Adjusts Price Target to $2 From $7
MT
William Blair Downgrades Mesoblast to Market Perform From Outperform
MT
Chardan Trims Price Target on Mesoblast to $1.50 From $2, Maintains Sell Rating
MT
Chardan Cuts Price Target on Mesoblast to $2 From $2.50 Reflecting Increased Share Count Dilution, Reiterates Sell Rating
MT
Cantor Fitzgerald Reiterates Mesoblast at Overweight With $23 Price Target
MT
Jefferies Downgrades Mesoblast to Hold From Buy
MT
Piper Sandler Starts Mesoblast at Overweight With $7 Price Target
MT
Chardan Lowers Mesoblast's Price Target to $2.50 From $6.50, Maintains Sell Rating
MT
MESOBLAST : Jefferies Downgrades Mesoblast to Hold From Buy
MT
MESOBLAST : Chardan Adjusts Mesoblast's Price Target to $6.50 From $7.50, Maintains Sell Rating
MT
Mesoblast : COVID-19 Drug Remestemcel-L's ARDS Trial Enhances Survival Rate in Patients
MT
MESOBLAST : Maxim Group Upgrades Mesoblast to Buy From Hold, Sets $18 Price Target
MT
MESOBLAST : Jefferies & Co Downgrades Mesoblast to Hold From Buy
MT
MESOBLAST : Maxim Downgrades Mesoblast to Hold From Buy
MT
MESOBLAST : RBC Capital Adjusts Mesoblast's Price Target to $11 From $12, Maintains Sector Perform-Speculative Risk Rating
MT
MESOBLAST : Chardan Downgrades Mesoblast to Sell From Neutral, Adjusts Price Target to $7.50 From $5.50
MT
MESOBLAST : HC Wainwright Adjusts Mesoblast's Price Target to $20 from $19, Keeps Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MSB Stock
  4. MESO Stock
  5. News Mesoblast Limited
  6. Analyst Reco.